Datamonitor, Sep 2008, Pages: 108
more to physicians, patients, payers and pharmacists will have the competitive edge.
Scope
- An overview of the current trends in pharmaceuticalportfoliomanagement
- Analysis of the ways in which
Business Insights, March 2004, Pages: 90
Winning Pharmaceutical R&D Strategies: Boosting profitability through improvements in portfoliomanagement, licensing and clinical trials, examines the core areas where companies can implement
GBI Research, Sep 2011, Pages: 153
in the pharmaceutical industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making
MCD Group LLC, Jan 2011, Pages: 203
categories targeted by specialty pharmaceutical companies, such as CNS disorders, pain management, men and women's health, rare diseases, and urology.
This 200+ page report is designed to act as a “guide
CBR Pharma Insights, Sep 2009
marketplace, need to focus on improving their lifecycle managementstrategies in order to maximize their portfolios sales over the long term.
In an increasingly difficult operating environment, optimizing LCM
John Wiley and Sons Ltd, April 2010, Pages: 331
of the Organization and Processes of Portfolio, Program, and Project Management (Pete Harpum).
5 PortfolioManagement in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products
Decision Resources, Inc., Oct 2011
Licensing strategies have never been more important to the pharmaceutical industry. Companies are competing on multiple fronts; they are inlicensing or acquiring innovative new drug candidates
Decision Resources, Inc., Aug 2011
economies. Pharmaceutical companies mostly prioritize Brazil, Russia, India, China, Mexico, and Turkey (BRIC-MT) for their emerging market strategies. Two of these markets, China and India, are in developing
Business Insights, June 2011, Pages: 153
The report reviews the key trends in pharmaceutical licensing, examining deal volumes, values and structure. Therapeutic focus is also covered along with detailed profiles of the strategies of 10
CBR Pharma Insights, March 2010
issues impacting pharmaceutical product development, while providing insight & analysis into the key strategies being used today to optimize pipeline performance. CBR Pharma Insights also examines how
Decision Resources, Inc., April 2011, Pages: 41
and with the emerging and developing BRIC-MT markets. It explores the differences and similarities between these diverse markets and discusses strategies as well as opportunities for pharmaceutical companies in NIEs
GBI Research, Feb 2010, Pages: 85
by pharmaceutical companies. This pharmaceutical and healthcare report provides information on the Lifestyle ManagementStrategies (LCM) market, the reasons why companies implement LCM strategies and the challenges
GBI Research, Aug 2011, Pages: 108
and challenges in the Indian pharmaceutical industry. The report analyzes effective strategies adopted by industry participants that shape industry dynamics. Further, the report provides competitive benchmarking
Venture Planning Group, Oct 2010, Pages: 121
and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market
GBI Research, Dec 2010, Pages: 71
patent portfoliomanagement. Furthermore, the report analyzes the patent strategies that shape the global markets. This report is built using data and information sourced from proprietary databases
Business Insights, May 2011, Pages: 96
market worldwide?
- What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the antibacterials market?
- What is the forecast commercial potential of the most
Datamonitor, Oct 2011, Pages: 40
managementstrategies of key companies in the neuropathic pain market.
- Assess trends in corporate strategies of companies active in the neuropathic pain arena and understand the impact of key recent
Venture Planning Group, Oct 2010, Pages: 121
and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market
Business Insights, June 2011, Pages: 160
The large number of impending patent expirations of blockbuster drugs will negatively impact the cardiovascular pharmaceutical segment. Evolving strategies in this segment such as in-licensing
